secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K
Filed at:   2023-02-06T23:59:59+00:00
Accession:  0000950170-23-001836
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

aTyr Pharma's partner Kyorin doses first patient in Phase 3 EFZO-FIT study; receives $10M milestone
--------------------------------------------------------------------------------

- Kyorin dosed first patient in Japan in global pivotal Phase 3 EFZO-FIT trial of efzofitimod for pulmonary sarcoidosis.
- Milestone payment of $10M triggered under Kyorin agreement; total upfront and milestones to date $20M.
- aTyr eligible for up to $155M additional development, regulatory, and sales milestones plus royalties on Japan net sales.
- Kyorin holds exclusive rights to develop and commercialize efzofitimod for all interstitial lung diseases in Japan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000095017023001836/0000950170-23-001836-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000095017023001836/life-20230206.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-001836

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer